Search

Your search keyword '"Frigeni M."' showing total 4 results
Start Over Author "Frigeni M." Journal leukemia
4 results on '"Frigeni M."'

1. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

Author

Fabiano Di Marco, Luca Novelli, Lucia Gandini, Ivano Riva, Caterina Micò, Francesco Landi, Marco Rizzi, Ferdinando Luca Lorini, Giuseppe Gritti, Marianna Damiani, Alessandro Rambaldi, Benjamin M. J. Owens, Leonardo Alborghetti, Stefano Fagiuoli, Karan J K Kanhai, Barbara Bottazzi, Federico Raimondi, Alberto Mantovani, Marco Frigeni, Gordana Tonkovic Reljanovic, Diego Ripamonti, Jonathan P Morgan, Gritti, G, Raimondi, F, Bottazzi, B, Ripamonti, D, Riva, I, Landi, F, Alborghetti, L, Frigeni, M, Damiani, M, Mico, C, Fagiuoli, S, Lorini, F, Gandini, L, Novelli, L, Morgan, J, Owens, B, Kanhai, K, Reljanovic, G, Rizzi, M, Di Marco, F, Mantovani, A, and Rambaldi, A

Subjects
Cancer Research, 2019-20 coronavirus outbreak, Letter, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Siltuximab, chemistry.chemical_compound, Antineoplastic Agents, Immunological, Medical research, Humans, Medicine, Prospective Studies, Interleukin 8, Pentraxin-3, Ventilators, Mechanical, SARS-CoV-2, business.industry, Interleukin-8, Antibodies, Monoclonal, COVID-19, Correction, Hematology, COVID-19 Drug Treatment, Survival Rate, Serum Amyloid P-Component, C-Reactive Protein, Oncology, chemistry, Acute Disease, Immunology, Infectious diseases, business
Published
2021
Full Text
View/download PDF

2. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.

Author

Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, Alborghetti L, Frigeni M, Damiani M, Micò C, Fagiuoli S, Lorini FL, Gandini L, Novelli L, Morgan JP, Owens BMJ, Kanhai KJK, Reljanovic GT, Rizzi M, Di Marco F, Mantovani A, and Rambaldi A

Subjects
Acute Disease, Antineoplastic Agents, Immunological therapeutic use, C-Reactive Protein genetics, COVID-19 immunology, COVID-19 virology, Humans, Interleukin-8 antagonists & inhibitors, Prospective Studies, SARS-CoV-2 isolation & purification, SARS-CoV-2 pathogenicity, Serum Amyloid P-Component genetics, Survival Rate, COVID-19 Drug Treatment, Antibodies, Monoclonal therapeutic use, C-Reactive Protein metabolism, COVID-19 therapy, Interleukin-8 blood, SARS-CoV-2 drug effects, Serum Amyloid P-Component metabolism, Ventilators, Mechanical
Published
2021
Full Text
View/download PDF

4. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Author

Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, Pulsoni A, Torres HA, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric C, Piazza F, Gentile M, Ferrari A, Pirisi M, Nassi L, Rattotti S, Frustaci A, Milella M, Cencini E, Defrancesco I, Ferretti VV, Bruno R, Hermine O, and Arcaini L

Subjects
Adult, Aged, Aged, 80 and over, B-Lymphocytes pathology, Female, Follow-Up Studies, Hepacivirus drug effects, Hepatitis C virology, Humans, Lymphoproliferative Disorders drug therapy, Lymphoproliferative Disorders virology, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Young Adult, Antiviral Agents therapeutic use, B-Lymphocytes drug effects, Hepacivirus isolation & purification, Hepatitis C complications, Interferon-alpha therapeutic use, Lymphoproliferative Disorders mortality
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results